Medicare Part D Premiums Will Decline
CMS announced that the average basic premium for Medicare Part D will decline in 2018. The average premium will be $33.50 per month, down $1.20 from the currently average premium of $34.70. The premium decline will occur despite the fact that spending for Part D continues to grow faster than spending for other parts of Medicare. This growth in spending has largely been driven by high-cost specialty drugs.
Molina Will Exit Utah and Wisconsin Exchanges
Facing losses for a second quarter, Molina Healthcare is reducing its involvement in the Affordable Care Act (ACA)’s health exchanges. The Wall Street Journal reported that Molina will leave the exchanges in Utah and Wisconsin and reduce involvement in the Washington state exchange. For the exchanges it is remaining in, Molina will increase premiums by an average of 55%. Molina’s move leaves 1 Wisconsin county with no exchange insurer.
Scientists Successfully Edit Genes in a Human Embryo
For the first time, scientists have edited the genes in a human embryo to repair a disease-causing mutation. The research represents a hope that babies could be protected from hereditary conditions, but also renews ethical concerns, reported The New York Times. The scientists were able to repair dozens of embryos and fix a mutation that causes a common, and often fatal, heart condition. The hypothesis is that babies born from the repaired embryos would not only not develop the disease themselves, but they would not pass the disease on to descendants.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks
April 30th 2024Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks
April 30th 2024Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Read More
2 Commerce Drive
Cranbury, NJ 08512